Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Tanaka, Junji  [Clear All Filters]
2023
Koresawa-Shimizu R, Suzuki R, Uehara Y, Hiramoto N, Sawa M, Fukuda T, Kataoka K, Kanda Y, Oyake T, Kubota Y, et al. Comparison of MEAM, MCEC and LEED high-dose chemotherapy followed by autologous stem cell transplantation in relapsed/refractory diffuse large B-cell lymphoma: data from the Japan Society for Hematopoietic and Cellular Therapy Registry. Bone Marrow Transplant. 2023.
Hirabayashi S, Kondo T, Nishiwaki S, Mizuta S, Doki N, Fukuda T, Uchida N, Ozawa Y, Kanda Y, Imanaka R, et al. Impact of MRD on clinical outcomes of unrelated hematopoietic stem cell transplantation in patients with Ph ALL: A retrospective nationwide study. Am J Hematol. 2023.
Konuma T, Itonaga H, Ishiyama K, Doki N, Uchida N, Sawa M, Katayama Y, Tanaka M, Ueda Y, Onizuka M, et al. Should a matched sibling donor still be considered the primary option for allogeneic hematopoietic cell transplantation in patients over 50 years of age with myelodysplastic syndrome?. Bone Marrow Transplant. 2023.
2022
Kanda Y, Doki N, Kojima M, Kako S, Inoue M, Uchida N, Onishi Y, Kamata R, Kotaki M, Kobayashi R, et al. Effect of cryopreservation in unrelated bone marrow and peripheral blood stem cell transplantation in the era of the COVID-19 pandemic. An update from the Japan Marrow Donor Program. Transplant Cell Ther. 2022.
2021
Kanda Y, Inoue M, Uchida N, Onishi Y, Kamata R, Kotaki M, Kobayashi R, Tanaka J, Fukuda T, Fujii N, et al. Cryopreservation of unrelated hematopoietic stem cells from a blood and marrow donor bank during the COVID-19 pandemic. A nationwide survey by the Japan Marrow Donor Program. Transplant Cell Ther. 2021.
2020
Akahoshi Y, Igarashi A, Fukuda T, Uchida N, Tanaka M, Ozawa Y, Kanda Y, Onizuka M, Ichinohe T, Tanaka J, et al. Impact of graft-versus-host disease and graft-versus-leukemia effect based on minimal residual disease in Philadelphia chromosome-positive acute lymphoblastic leukemia. Br J Haematol. 2020.
Akahoshi Y, Nishiwaki S, Arai Y, Harada K, Najima Y, Kanda Y, Shono K, Ota S, Fukuda T, Uchida N, et al. Reduced-intensity conditioning is a reasonable alternative for Philadelphia chromosome-positive acute lymphoblastic leukemia among elderly patients who have achieved negative minimal residual disease: a report from the Adult Acute Lymphoblastic Leukemia W. Bone Marrow Transplant. 2020.
2019
Hangai M, Urayama KY, Tanaka J, Kato K, Nishiwaki S, Koh K, Noguchi M, Kato K, Yoshida N, Sato M, et al. Allogeneic stem cell transplantation for acute lymphoblastic leukemia in adolescents and young adults. Biol Blood Marrow Transplant. 2019.
Shinohara A, Oshima K, Fuji S, Umeda K, Kako S, Kurokawa M, Tsukada N, Kasai M, Kondo T, Hashii Y, et al. Hematopoietic stem cell transplantation in solid organ recipients with emphasis on transplant complications: a nationwide retrospective survey on behalf of the JSHCT, transplant complications working group. Biol Blood Marrow Transplant. 2019.
Fujimoto A, Hiramoto N, Yamasaki S, Inamoto Y, Uchida N, Maeda T, Mori T, Kanda Y, Kondo T, Shiratori S, et al. Risk factors and predictive scoring system for post-transplant lymphoproliferative disorder after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019.
2018
Akahoshi Y, Mizuta S, Shimizu H, Uchida N, Fukuda T, Kanamori H, Onizuka M, Ozawa Y, Ohashi K, Ohta S, et al. Additional cytogenetic abnormalities with Philadelphia chromosome-positive acute lymphoblastic leukemia on allogeneic stem cell transplantation in the tyrosine kinase inhibitor era. Biol Blood Marrow Transplant. 2018.
2014
Kato H, Kawase T, Kako S, Mizuta S, Kurokawa M, Mori T, Ohashi K, Iwato K, Miyamura K, Hidaka M, et al. Analysis of outcomes following autologous stem-cell transplantation in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia during the first complete remission. Haematologica. 2014.